Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer

References

• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.000000000000063026291008
   PubMed Web of Science ®Google Scholar
• von der Thüsen JH, Tham YS, Pattenden H, et al. Prognostic significance of predominant histologic pattern and nuclear grade in resected adenocarcinoma of the lung: potential parameters for a grading system. J Thorac Oncol. 2013;8(1):37–44. doi:10.1097/JTO.0b013e318276274e23242436
   PubMed Web of Science ®Google Scholar
• Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012;25(8):1117–1127. doi:10.1038/modpathol.2012.5822499226
   PubMed Web of Science ®Google Scholar
• Kadota K, Nitadori JI, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage i lung adenocarcinomas. J Thorac Oncol. 2015;10(5):806–814. doi:10.1097/JTO.000000000000048625629637
   PubMed Web of Science ®Google Scholar
• Kadota K, Kushida Y, Kagawa S, et al. Cribriform subtype is an independent predictor of recurrence and survival after adjustment for the eighth edition of TNM staging system in patients with resected lung adenocarcinoma. J Thorac Oncol. 2019;14(2):245–254. doi:10.1016/j.jtho.2018.09.02830336325
   PubMed Web of Science ®Google Scholar
• Moreira AL, Ocampo PSS, Xia Y, et al. A grading system for invasive pulmonary adenocarcinoma: a proposal from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2020;15(10):1599–1610. doi:10.1016/j.jtho.2020.06.00132562873
   PubMed Web of Science ®Google Scholar
• Zhu J, Li R, Tiselius E, et al. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2017;12(12):Cd011300. doi:10.1002/14651858.CD011300.pub229247502
   PubMed Web of Science ®Google Scholar
• Mohsenzadegan M, Peng RW, Roudi R. Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: what we know and future landscape. J Cell Physiol. 2020;235(1):74–86. doi:10.1002/jcp.2897731222740
   PubMed Web of Science ®Google Scholar
• Tartarone A, Roviello G, Lerose R, Roudi R, Aieta M, Zoppoli P. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. Future Oncol. 2019;15(20):2423–2433. doi:10.2217/fon-2018-086831237152
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang R, Shen X, et al. Minor components of micropapillary and solid subtypes in lung adenocarcinoma are predictors of lymph node metastasis and poor prognosis. Ann Surg Oncol. 2016;23(6):2099–2105. doi:10.1245/s10434-015-5043-926842488
   PubMed Web of Science ®Google Scholar
• Tsao MS, Marguet S, Le Teuff G, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol. 2015;33(30):3439–3446. doi:10.1200/JCO.2014.58.833525918286
   PubMed Web of Science ®Google Scholar
• Suzuki M, Yokose T, Nakayama H. Prognostic contribution of non-predominant solid and micropapillary components in lung adenocarcinomas. J Thorac Dis. 2017;9(3):504–506. doi:10.21037/jtd.2017.03.1528449456
   PubMed Web of Science ®Google Scholar
• Saruwatari K, Ikemura S, Sekihara K, et al. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations. Lung Cancer. 2016;91:7–14. doi:10.1016/j.lungcan.2015.11.01226711928
   PubMed Web of Science ®Google Scholar
• Pyo JS, Kim JH. Clinicopathological significance of micropapillary pattern in lung adenocarcinoma. Pathol Oncol Res. 2018;24(3):547–555. doi:10.1007/s12253-017-0274-728685219
   PubMed Web of Science ®Google Scholar
• Ma M, She Y, Ren Y, et al. Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma. J Thorac Dis. 2018;10(9):5384–5393. doi:10.21037/jtd.2018.08.6430416786
   PubMed Web of Science ®Google Scholar
• Kuang M, Shen X, Yuan C, et al. Clinical significance of complex glandular patterns in lung adenocarcinoma: clinicopathologic and molecular study in a large series of cases. Am J Clin Pathol. 2018;150(1):65–73. doi:10.1093/ajcp/aqy03229746612
   PubMed Web of Science ®Google Scholar
• Kadota K, Yeh YC, Sima CS, et al. The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol. 2014;27(5):690–700. doi:10.1038/modpathol.2013.18824186133
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6(9):1496–1504. doi:10.1097/JTO.0b013e318221f70121642859
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203. doi:10.1016/j.chest.2016.10.01027780786
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.00926762738
   PubMed Web of Science ®Google Scholar
• Wu C, Zhao C, Yang Y, et al. High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules. J Thorac Oncol. 2015;10(5):778–783. doi:10.1097/JTO.000000000000048725629635
   PubMed Web of Science ®Google Scholar
• Li W, Ren S, Li J, et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer. 2014;84(3):295–300. doi:10.1016/j.lungcan.2014.03.01124685306
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–285.21252716
   PubMed Web of Science ®Google Scholar
• Riely GJ, Travis WD. Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma? Eur Respir J. 2014;43(5):1240–1242. doi:10.1183/09031936.0004881424789948
   PubMed Web of Science ®Google Scholar
• Kuo SW, Chen JS, Huang PM, Hsu HH, Lai HS, Lee JM. Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2014;148(4):1200–1207.e1203. doi:10.1016/j.jtcvs.2014.04.03824993621
   PubMed Web of Science ®Google Scholar
• Da Cruz V, Yvorel V, Casteillo F, et al. Histopathological subtyping is a prognostic factor in stage IV lung adenocarcinoma. Lung Cancer. 2020;147:77–82. doi:10.1016/j.lungcan.2020.07.01032682188
   PubMed Web of Science ®Google Scholar
• Casteillo F, Guy JB, Dal-Col P, et al. Pathologic subtypes of lung adenocarcinoma brain metastasis is a strong predictor of survival after resection. Am J Surg Pathol. 2018;42(12):1701–1707. doi:10.1097/PAS.000000000000116130222604
   PubMed Web of Science ®Google Scholar
• Wang W, Hu Z, Zhao J, et al. Both the presence of a micropapillary component and the micropapillary predominant subtype predict poor prognosis after lung adenocarcinoma resection: a meta-analysis. J Cardiothorac Surg. 2020;15(1):154. doi:10.1186/s13019-020-01199-832600473
   PubMed Web of Science ®Google Scholar
• Dong ZY, Zhang C, Li YF, et al. Genetic and immune profiles of solid predominant lung adenocarcinoma reveal potential immunotherapeutic strategies. J Thorac Oncol. 2018;13(1):85–96. doi:10.1016/j.jtho.2017.10.02029127022
   PubMed Web of Science ®Google Scholar
• Yaldiz D, Ors Kaya S, Ceylan KC, et al. Prognostic affect of predominant histologic subtypes in resected pulmonary adenocarcinomas. Balkan Med J. 2019. doi:10.4274/balkanmedj.galenos.2019.2019.1.130
   PubMed Web of Science ®Google Scholar
• Chang C, Sun X, Zhao W, et al. Minor components of micropapillary and solid subtypes in lung invasive adenocarcinoma (≤ 3 cm): PET/CT findings and correlations with lymph node metastasis. Radiol Med. 2020;125(3):257–264. doi:10.1007/s11547-019-01112-x31823295
   PubMed Web of Science ®Google Scholar
• Campos-Parra AD, Avilés A, Contreras-Reyes S, et al. Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. Eur Respir J. 2014;43(5):1439–1447. doi:10.1183/09031936.0013881324435003
   PubMed Web of Science ®Google Scholar
• Fathi Z, Syn NL, Zhou JG, Roudi R. Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention. J Hum Genet. 2018;63(7):783–794. doi:10.1038/s10038-018-0450-y29666465
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a Randomised, Open-Label, Phase 3 Study. Lancet Oncol. 2018;19(1):139–148. doi:10.1016/S1470-2045(17)30729-529174310
   PubMed Web of Science ®Google Scholar
• Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, Phase 2 trial. Lancet Respir Med. 2018;6(11):863–873. doi:10.1016/S2213-2600(18)30277-730150014
   PubMed Web of Science ®Google Scholar
• Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020;383(18):1711–1723. doi:10.1056/NEJMoa202707132955177
   PubMed Web of Science ®Google Scholar
• Roviello G, Zanotti L, Cappelletti MR, et al. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? Clin Exp Med. 2018;18(1):15–20. doi:10.1007/s10238-017-0460-728391544
   PubMed Web of Science ®Google Scholar